Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 in Combination With Paclitaxel ± Bevacizumab in Platinum-resistant Ovarian Cancer
NCT07042802Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in ovarian cancer, sponsored by Leads Biolabs. Started Dec 2025; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07042802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042802.